Art. -Nr.: HY-W100287

Murrayafoline A

Kundenbewertung

Based on 1 Customer Validation

Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.73%
CAS. Nr.: 4532-33-6
Formel: C₁₄H₁₃NO
Molecular Weight:211.26

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Murrayafoline A Chemical Structure

CAS. Nr.: 4532-33-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

Alle IKK Isoform-spezifische Produkte anzeigen :

Alle JNK Isoform-spezifische Produkte anzeigen :

Alle Wnt Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
PBMC	IC₅₀	7 μM Compound: 58	Inhibition of TNF-alpha production in LPS-stimulated human PBMC cells Inhibition of TNF-alpha production in LPS-stimulated human PBMC cells	[PMID: 33454546]
PBMC	IC₅₀	8.4 μM Compound: 58	Inhibition of IL6 production in LPS-stimulated human PBMC cells Inhibition of IL6 production in LPS-stimulated human PBMC cells	[PMID: 33454546]

In Vitro

Murrayafoline A (5-20 μM, 24 h) potently inhibits the production of neuroinflammation mediators, such as nitric oxide (NO), TNF-α, IL-6 and IL-1β in LPS (HY-D1056)-induced BV-2 microglial cells, an effect that can be significantly antagonized by Sp1 knockdown^[1].
Murrayafoline A (20 μM, 2 h) directly interacts with Sp1, as confirmed by surface plasmon resonance (SPR) with a dissociation constant (K_D) of 11.34 pM in BV-2 cells^[1].
Murrayafoline A (20 μM) inhibits IKKβ/NF-κB and p38/JNK MAPKs pathways that can be markedly reversed by Sp1 knockdown in LPS-induced BV-2 cells^[1].
Murrayafoline A (1-5 μM, 24 h) inhibits PDGF-BB-stimulated proliferation of vascular smooth muscle cells (VSMCs), DNA synthesis and induces a G0/G1-phase arrest^[2].
Murrayafoline A (1-5 μM) down-regulates the expression of cyclin D1, cyclin E, CDK2, CDK4, and PCNA, and inhibits the phosphorylation of pRb in PDGF-BB-stimulated VSMCs^[2].
Murrayafoline A (5-40 μM, 15 h) dose-dependently reduces LiCl- and Wnt3a-CM-induced TOPFlash reporter activity and SEAP activity in HEK293 reporter cells without affecting FOPFlash activity^[3].
Murrayafoline A (20-40 μM, 15 h) decreases cytosolic β-catenin level in LiCl- and Wnt3a-CM-treated HEK293 reporter cells^[3].
Murrayafoline A (10-80 μM, 15-48 h) reduces cytosolic β-catenin level, cyclin D1 and c-myc levels in SW480 and HCT-116 colon cancer cells and dose-dependently inhibits the proliferation of SW480, DLD-1, HCT-116 and LS174T colon cancer cells^[3].
Murrayafoline A (25 μM, 2 min) increases cell shortening, increases L-type Ca²⁺ current, enhances PKC phosphorylation and enhances the rate of contraction in rat ventricular myocytes^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[2]

Cell Line:

Vascular smooth muscle cells (VSMCs)
Concentration:

1, 3, 5 μM
Incubation Time:

24 h
Result:

Increased the cell population in G0/G1phase.
Decreased the S, G2, and M phases.

Cell Cycle Analysis^[3]

Cell Line:

SW480, DLD-1, HCT-116 and LS174T colon cancer cells
Concentration:

5, 10, 20, 40, 80 μM
Incubation Time:

48 h
Result:

Inhibited the proliferation of SW480, DLD-1, HCT-116 and LS174T colon cancer cells.

In Vivo

Murrayafoline A (10-50 mg/kg, 1h pretreatment , single dose) demonstrates excellent anti-neuroinflammatory efficacy in LPS-induced neuroinflammation mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

LPS (1.5 mg/kg) was used to induce neuroinflammation in 6-7-week-old male Balb/c mice^[1]
Dosage:

10, 50 mg/kg
Administration:

1h pretreatment for a single dose
Result:

Reduced the expression of Iba-1, TNF-α, and IL-6 in the brains of LPS-induced male Balb/c mice.
Increased the number of Nissl bodies in the brains of LPS-induced male Balb/c mice.

Chemical Information

CAS. Nr. 4532-33-6
Appearance Solid
Molecular Weight 211.26
Formel C₁₄H₁₃NO
Color White to light yellow
SMILES

CC1=CC2=C(C(=C1)OC)NC3=CC=CC=C23
Structure Classification
- Alkaloids
- Carbazole Alkaloids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (473.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.7335 mL

23.6675 mL

47.3350 mL

5 mM

0.9467 mL

4.7335 mL

9.4670 mL

10 mM

0.4734 mL

2.3668 mL

4.7335 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (11.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (11.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Li CH, et al. Natural carbazole alkaloid murrayafoline A displays potent anti-neuroinflammatory effect by directly targeting transcription factor Sp1 in LPS-induced microglial cells. Bioorg Chem. 2022 Dec;129:106178. [Content Brief]

[2]. Han JH, et al. Murrayafoline A Induces a G0/G1-Phase Arrest in Platelet-Derived Growth Factor-Stimulated Vascular Smooth Muscle Cells. Korean J Physiol Pharmacol. 2015 Sep;19(5):421-6. [Content Brief]

[3]. Choi H, et al. Murrayafoline A attenuates the Wnt/beta-catenin pathway by promoting the degradation of intracellular beta-catenin proteins. Biochem Biophys Res Commun. 2010 Jan 1;391(1):915-20. [Content Brief]

[4]. Chidipi B, et al. Enhancement of contraction and L-type Ca(2+) current by murrayafoline-A via protein kinase C in rat ventricular myocytes. Eur J Pharmacol. 2016 Aug 5;784:33-41. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.7335 mL	23.6675 mL	47.3350 mL	118.3376 mL
	5 mM	0.9467 mL	4.7335 mL	9.4670 mL	23.6675 mL
	10 mM	0.4734 mL	2.3668 mL	4.7335 mL	11.8338 mL
	15 mM	0.3156 mL	1.5778 mL	3.1557 mL	7.8892 mL
	20 mM	0.2367 mL	1.1834 mL	2.3668 mL	5.9169 mL
	25 mM	0.1893 mL	0.9467 mL	1.8934 mL	4.7335 mL
	30 mM	0.1578 mL	0.7889 mL	1.5778 mL	3.9446 mL
	40 mM	0.1183 mL	0.5917 mL	1.1834 mL	2.9584 mL
	50 mM	0.0947 mL	0.4734 mL	0.9467 mL	2.3668 mL
	60 mM	0.0789 mL	0.3945 mL	0.7889 mL	1.9723 mL
	80 mM	0.0592 mL	0.2958 mL	0.5917 mL	1.4792 mL
	100 mM	0.0473 mL	0.2367 mL	0.4734 mL	1.1834 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Murrayafoline A

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Antihypertensive Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Extracellular Vesicles (EVs) Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Alle IKK Isoform-spezifische Produkte anzeigen

Alle JNK Isoform-spezifische Produkte anzeigen

Alle Wnt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Murrayafoline A Related Classifications